AI-Powered Research

18=Age=40
BMI = 25
Being single
Not having acute and chronic diseases such as: cardiovascular disease, kidney, liver, diabetes, hypothyroidism, hyperthyroidism, asthma, neoplastic, hyperprolactinemia, malabsorption disorders, hypertension, dyslipidemia, (new or during 6 months).
No Depression
Not following a specific diet.
Not following a specific exercise program.
Non-use of drugs such as contraceptive pills (Oral contraceptive pill), hormonal drugs, anti-diabetic drugs, anti-obesity drugs, antioxidant supplements and multivitamin minerals, blood lipid lowering drugs.
Not smoking
Not allergic to pomegranate and its products.
Not consuming pomegranates and pomegranate-containing products at least 2 months before starting the study

Exclusion Criteria

Pregnancy
Not consuming Concentrated Pomegranate Juice completely
Not willing to continue participating in the study

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of malondialdehyde in women with polycystic ovary syndrome. Timepoint: Baseline and 8 weeks after starting the study. Method of measurement: Measurement of serum malondialdehyde by calorimetric method using kiazist kit.

Secondary Outcome Measures

Name	Time	Method
Evaluation of total antioxidant capacity in women with polycystic ovary syndrome. Timepoint: Baseline and 8 weeks after starting the study. Method of measurement: Measurement of serum total antioxidant capacity by cupric reducing antioxidant capacity (CUPRAC) method using kiazist kit.;Evaluation of insulin resistance in women with polycystic ovary syndrome. Timepoint: Baseline and 8 weeks after starting the study. Method of measurement: Measurement of Insulin Resistance Using Formula (fasting plasma glucose (mMol/L) × insulin (µIU/mL))/22.5. The levels of serum insulin will be determined using ELISA kit (AccuBind, Monobind Inc., USA) and fasting blood sugar will be measured by enzymatic photometric method using standard kits (Pars Azmun, Tehran, Iran).;Depression score. Timepoint: Baseline and 8 weeks after starting the study. Method of measurement: Depression Anxiety Stress Scale-21 (DASS-21) questionnaire.